Gsk (GSK) Net Income towards Common Stockholders (2009 - 2026)

Gsk's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $583.6 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 69.68% year-over-year to $583.6 million; the TTM figure through Jun 2026 stood at $9.7 billion (up 44.16% YoY), while the FY2025 annual figure was $7.5 billion, up 128.97% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at $583.6 million, down from $2.3 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $17.5 billion in Q4 2022, with the low at -$75.4 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is $2.0 billion (2023), against an average of $3.5 billion.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 104.06% in 2024, then soared 3704.42% in 2025.
• Gsk's Net Income towards Common Stockholders stood at $17.5 billion in 2022, then slumped by 77.97% to $3.9 billion in 2023, then fell by 26.31% to $2.8 billion in 2024, then surged by 43.24% to $4.1 billion in 2025, then sank by 85.69% to $583.6 million in 2026.
• Business Quant data shows GSK's Net Income towards Common Stockholders at $583.6 million in Q2 2026, $2.3 billion in Q1 2026, and $4.1 billion in Q4 2025.